ArticleDermatology and therapy2026
The Economic Burden of Chronic Urticaria in Portugal: A Patient-Reported Cost-of-Illness Study.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChronic urticaria (CU) substantially impairs an individual's quality of life, yet its costs are seldom quantified and no full cost-of-illness analysis has been published for Portugal. We have estimated the annual societal cost associated with CU in Portuguese adults and examined whether quality-of-life impairment is associated with productivity loss.
methodsThis was a cross-sectional, patient-reported study of 147 adults with a physician-established CU diagnosis, recruited through the national patient association in 2021-2022. A bottom-up, prevalence-based design was applied from a societal perspective. Estimates were post-stratified by disease severity to the AWARE study distribution, and both weighted and unweighted estimates are reported. Per-patient costs were the primary outcome, and national aggregates were secondary outcomes. Regression models adjusted for the severity strata used in the weighting related productivity loss to the Dermatology Life Quality Index (DLQI). Costs are expressed in 2022 euros.
resultsThe weighted mean annual societal cost was estimated at €4687 per patient (unweighted €7014). Presenteeism accounted for 62.4% (€2927) of the total; employed patients lost 64.2 working days/year [95% confidence interval (CI) 40.6-87.8] to reduced productivity at work, against 1.5 days of absence. Direct costs were €1132 per patient (unweighted €2500), of which patients paid 64% out of pocket. Among employed patients, each DLQI point was associated with €270 (95% CI 131-408) of annual productivity loss after adjustment for severity, and the estimate was unchanged when the work-related DLQI item was excluded. National estimates ranged from €202 million to €927 million per year across prevalence scenarios.
conclusionsIn this self-selected sample, the societal cost of CU was dominated by presenteeism, and the most direct costs were borne by patients. Poorer quality of life was associated with greater productivity loss independently of disease severity. Patient-level estimates are more robust than national extrapolations.
Indexed as
Identifiers
42875675What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.